vs
DoubleVerify Holdings, Inc.（DV）与Ultragenyx Pharmaceutical Inc.（RARE）财务数据对比。点击上方公司名可切换其他公司
Ultragenyx Pharmaceutical Inc.的季度营收约是DoubleVerify Holdings, Inc.的1.0倍（$207.3M vs $205.6M），DoubleVerify Holdings, Inc.净利率更高（14.3% vs -62.0%，领先76.3%），Ultragenyx Pharmaceutical Inc.同比增速更快（25.9% vs 7.9%），DoubleVerify Holdings, Inc.自由现金流更多（$62.1M vs $-100.8M），过去两年Ultragenyx Pharmaceutical Inc.的营收复合增速更高（38.0% vs 20.8%）
DoubleVerify Holdings是一家专注于媒体测量、分析及验证的技术服务商，核心业务为品牌安全、广告可见度、反广告欺诈等，帮助广告主、发布商及平台方优化数字广告投放效果，保障营销投入的ROI，业务覆盖全球多个市场。
Ultragenyx Pharmaceutical Inc.是一家总部位于美国的生物制药企业，专注于研发罕见病和超罕见遗传病的创新治疗方案，这类疾病目前大多无获批疗法，存在大量未被满足的临床需求。公司覆盖生物制剂、小分子药物、基因疗法、反义寡核苷酸及mRNA等多种药物技术平台，研发管线涵盖骨骼、内分泌、代谢、肌肉及中枢神经系统疾病领域。
DV vs RARE — 直观对比
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $205.6M | $207.3M |
| 净利润 | $29.3M | $-128.6M |
| 毛利率 | 82.5% | — |
| 营业利润率 | 18.4% | -54.7% |
| 净利率 | 14.3% | -62.0% |
| 营收同比 | 7.9% | 25.9% |
| 净利润同比 | 25.3% | 3.5% |
| 每股收益（稀释后） | $0.18 | $-1.28 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
| Q4 25 | $205.6M | $207.3M | ||
| Q3 25 | $188.6M | $159.9M | ||
| Q2 25 | $189.0M | $166.5M | ||
| Q1 25 | $165.1M | $139.3M | ||
| Q4 24 | $190.6M | $164.6M | ||
| Q3 24 | $169.6M | $139.5M | ||
| Q2 24 | $155.9M | $147.0M | ||
| Q1 24 | $140.8M | $108.8M |
| Q4 25 | $29.3M | $-128.6M | ||
| Q3 25 | $10.2M | $-180.4M | ||
| Q2 25 | $8.8M | $-115.0M | ||
| Q1 25 | $2.4M | $-151.1M | ||
| Q4 24 | $23.4M | $-133.2M | ||
| Q3 24 | $18.2M | $-133.5M | ||
| Q2 24 | $7.5M | $-131.6M | ||
| Q1 24 | $7.2M | $-170.7M |
| Q4 25 | 82.5% | — | ||
| Q3 25 | 82.3% | — | ||
| Q2 25 | 82.5% | — | ||
| Q1 25 | 81.2% | — | ||
| Q4 24 | 82.0% | — | ||
| Q3 24 | 82.6% | — | ||
| Q2 24 | 83.3% | — | ||
| Q1 24 | 81.1% | — |
| Q4 25 | 18.4% | -54.7% | ||
| Q3 25 | 11.2% | -106.9% | ||
| Q2 25 | 7.2% | -64.8% | ||
| Q1 25 | 4.1% | -102.6% | ||
| Q4 24 | 20.3% | -74.3% | ||
| Q3 24 | 15.2% | -94.6% | ||
| Q2 24 | 7.1% | -79.1% | ||
| Q1 24 | 4.9% | -151.9% |
| Q4 25 | 14.3% | -62.0% | ||
| Q3 25 | 5.4% | -112.8% | ||
| Q2 25 | 4.6% | -69.0% | ||
| Q1 25 | 1.4% | -108.5% | ||
| Q4 24 | 12.3% | -80.9% | ||
| Q3 24 | 10.7% | -95.7% | ||
| Q2 24 | 4.8% | -89.5% | ||
| Q1 24 | 5.1% | -156.8% |
| Q4 25 | $0.18 | $-1.28 | ||
| Q3 25 | $0.06 | $-1.81 | ||
| Q2 25 | $0.05 | $-1.17 | ||
| Q1 25 | $0.01 | $-1.57 | ||
| Q4 24 | $0.14 | $-1.34 | ||
| Q3 24 | $0.10 | $-1.40 | ||
| Q2 24 | $0.04 | $-1.52 | ||
| Q1 24 | $0.04 | $-2.03 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $259.0M | $421.0M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $1.1B | $-80.0M |
| 总资产 | $1.4B | $1.5B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
| Q4 25 | $259.0M | $421.0M | ||
| Q3 25 | $200.7M | $202.5M | ||
| Q2 25 | $216.8M | $176.3M | ||
| Q1 25 | $174.3M | $127.1M | ||
| Q4 24 | $310.6M | $174.0M | ||
| Q3 24 | $362.6M | $150.6M | ||
| Q2 24 | $338.8M | $480.7M | ||
| Q1 24 | $334.3M | $112.3M |
| Q4 25 | $1.1B | $-80.0M | ||
| Q3 25 | $1.1B | $9.2M | ||
| Q2 25 | $1.1B | $151.3M | ||
| Q1 25 | $1.0B | $144.2M | ||
| Q4 24 | $1.1B | $255.0M | ||
| Q3 24 | $1.1B | $346.8M | ||
| Q2 24 | $1.1B | $432.4M | ||
| Q1 24 | $1.1B | $140.3M |
| Q4 25 | $1.4B | $1.5B | ||
| Q3 25 | $1.3B | $1.2B | ||
| Q2 25 | $1.3B | $1.3B | ||
| Q1 25 | $1.2B | $1.3B | ||
| Q4 24 | $1.3B | $1.5B | ||
| Q3 24 | $1.3B | $1.5B | ||
| Q2 24 | $1.3B | $1.6B | ||
| Q1 24 | $1.3B | $1.3B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $72.7M | $-99.8M |
| 自由现金流经营现金流 - 资本支出 | $62.1M | $-100.8M |
| 自由现金流率自由现金流/营收 | 30.2% | -48.6% |
| 资本支出强度资本支出/营收 | 5.1% | 0.5% |
| 现金转化率经营现金流/净利润 | 2.48× | — |
| 过去12个月自由现金流最近4个季度 | $172.7M | $-472.0M |
8季度趋势，按日历期对齐
| Q4 25 | $72.7M | $-99.8M | ||
| Q3 25 | $51.2M | $-91.4M | ||
| Q2 25 | $49.6M | $-108.3M | ||
| Q1 25 | $37.7M | $-166.5M | ||
| Q4 24 | $37.4M | $-79.3M | ||
| Q3 24 | $54.6M | $-67.0M | ||
| Q2 24 | $35.9M | $-77.0M | ||
| Q1 24 | $31.8M | $-190.7M |
| Q4 25 | $62.1M | $-100.8M | ||
| Q3 25 | $39.0M | $-92.7M | ||
| Q2 25 | $40.1M | $-110.7M | ||
| Q1 25 | $31.4M | $-167.8M | ||
| Q4 24 | $30.0M | $-79.5M | ||
| Q3 24 | $48.4M | $-68.6M | ||
| Q2 24 | $28.7M | $-79.0M | ||
| Q1 24 | $25.4M | $-193.9M |
| Q4 25 | 30.2% | -48.6% | ||
| Q3 25 | 20.7% | -58.0% | ||
| Q2 25 | 21.2% | -66.5% | ||
| Q1 25 | 19.0% | -120.5% | ||
| Q4 24 | 15.8% | -48.3% | ||
| Q3 24 | 28.5% | -49.2% | ||
| Q2 24 | 18.4% | -53.7% | ||
| Q1 24 | 18.0% | -178.2% |
| Q4 25 | 5.1% | 0.5% | ||
| Q3 25 | 6.4% | 0.8% | ||
| Q2 25 | 5.0% | 1.5% | ||
| Q1 25 | 3.8% | 1.0% | ||
| Q4 24 | 3.9% | 0.1% | ||
| Q3 24 | 3.7% | 1.2% | ||
| Q2 24 | 4.6% | 1.4% | ||
| Q1 24 | 4.5% | 3.0% |
| Q4 25 | 2.48× | — | ||
| Q3 25 | 5.02× | — | ||
| Q2 25 | 5.66× | — | ||
| Q1 25 | 15.95× | — | ||
| Q4 24 | 1.60× | — | ||
| Q3 24 | 3.00× | — | ||
| Q2 24 | 4.80× | — | ||
| Q1 24 | 4.44× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
DV
| Activation | $116.5M | 57% |
| Measurement | $69.6M | 34% |
| Supply Side | $19.5M | 9% |
RARE
| Royalty | $105.6M | 51% |
| Products | $101.7M | 49% |
